A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
about
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapyPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Melanoma: from mutations to medicineNovel non-AR therapeutic targets in castrate resistant prostate cancerIdentification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.Oblimersen for the treatment of patients with chronic lymphocytic leukemia.Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Update on options for treatment of metastatic castration-resistant prostate cancerFeasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.G3139 (Genasense) in patients with advanced merkel cell carcinomaChemotherapeutic approaches for targeting cell death pathways.Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapyAntisense-based cancer therapeutics: are we there yet?Interfering with cell-survival signalling as a treatment strategy for prostate cancer.A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth.YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene ExpressionOblimersen in the treatment of metastatic melanoma.Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.Docetaxel-based combination therapy for castration-resistant prostate cancer.Recent developments in prostate cancer biomarker research: therapeutic implications.Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).Chemotherapy in Prostate Cancer.Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.Regulation of cell death in cancer-possible implications for immunotherapy.Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.Targeting apoptosis signaling pathways for anticancer therapyThymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference.The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.
P2860
Q24635408-53F1C4D5-C934-4468-A1CB-C7CB14937215Q26771601-996800FF-0D3A-4310-B62F-AA957EEDE036Q27024061-1F50CFAA-DCC0-4B46-A2E7-B2AE72F4B913Q28383663-0E48FECF-67C1-4C38-A826-5CEC755495E4Q30423722-82D17E8F-2E53-4B58-ADB1-4A5D96A4B69EQ33379565-22262026-AD30-4BED-A171-6CC91BBF6273Q33383770-AF2BF476-184D-451D-B1CC-525965FFC087Q33393931-2F9BE27B-1E0C-474D-98E9-AD0B865300A8Q33642278-2D34946B-084C-4639-A59D-72F28CA0C406Q33956051-AB4F0437-675E-450E-AEB9-80334D03B51DQ34063991-B545B365-A746-4A9A-B6EE-BC79C2729157Q35029577-0F3004E3-5481-4D8E-8E88-F0EE41E80001Q35094229-CCEE2CF7-F36C-40F7-BB64-71FD51AF73C8Q35099238-E91F87FB-F878-4010-A3DF-D2D21776B956Q36458427-4C17F1F8-587B-408B-9922-3407185749BFQ36474196-63ECE411-CA49-47A3-984F-B769DD1FB6D6Q36564026-3438EBD5-A61C-4882-9052-38E9C9FE388CQ36597347-AAC6B623-7670-4B97-8993-4264DAD82DAEQ36623633-960E1137-EB1E-4D04-BFB4-DAF27B3383B9Q36696114-6896053B-49C2-478B-ADDB-80CBA85F5313Q36791090-B84D08FA-7924-42A6-836B-C21BD49C362AQ36839762-829F997A-9F1B-49EE-8AAB-A0F1285E4DF2Q37120213-D6594400-07F0-4594-BD50-9ADD21C1694FQ37255452-9555651F-AEEF-4FDF-896A-38464B2AB6BDQ37521403-F8FC6FB7-A70C-44F8-9950-D582EEAD2843Q37575815-AF5D63AC-5109-421C-A9E8-5C7B6A3CD96FQ37721016-25E23203-A83D-4A0B-89EA-43713282D9D0Q37827186-C63F4D8C-2E53-4C88-9A2A-24AE3A6C464CQ37869144-93CBE458-C4DC-4AA8-96C4-5FB6E49C5449Q37950459-E789FA83-FD97-4475-A191-E4556668D8C1Q38555599-FBCB11FF-3203-46C6-B3D1-EC4C2284C5B8Q38832738-0E673C31-305C-4F04-9B91-1BD89F569849Q39339490-FF3FB2DB-5361-4CCF-A6F0-06827537D25EQ39461469-AAA346AE-311F-4B26-B9F5-10FF140044DEQ39612017-6E5F0FF3-AFD1-4C05-9728-286DACEE73AAQ39888116-9CFE570C-E633-4420-8E49-0BE15236238DQ42153007-7B6F2269-CA8A-4094-AAF5-7D89D962DDF9Q42175008-06958FE4-1EAD-4E93-97DF-17233978E45CQ46540346-86C8361C-1840-4F0A-A5F2-3D63AF3A0045Q55356724-19471007-35CC-4AEA-803D-0B87FD808156
P2860
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A phase II, pharmacokinetic, a ...... ne-refractory prostate cancer.
@en
A phase II, pharmacokinetic, a ...... ne-refractory prostate cancer.
@nl
type
label
A phase II, pharmacokinetic, a ...... ne-refractory prostate cancer.
@en
A phase II, pharmacokinetic, a ...... ne-refractory prostate cancer.
@nl
prefLabel
A phase II, pharmacokinetic, a ...... ne-refractory prostate cancer.
@en
A phase II, pharmacokinetic, a ...... ne-refractory prostate cancer.
@nl
P2093
P1476
A phase II, pharmacokinetic, a ...... ne-refractory prostate cancer.
@en
P2093
Amita Patnaik
Anthony W Tolcher
Chris Takimoto
Elzbieta Izbicka
Eric Rowinsky
Garry Schwartz
Ian Thompson
Kristin Berg
P304
P356
10.1158/1078-0432.CCR-04-2145
P407
P577
2005-05-01T00:00:00Z